title: Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
abstract: BACKGROUND
  The first CE-approved bioresorbable vascular scaffold (BVS) is effective at treating simple lesions and stable coronary artery disease, but it has yet to be assessed versus the best-in-class drug-eluting stents (DES).
  
  
  OBJECTIVE
  This study sought to compare the performance of a BVS with that of everolimus-eluting stents (EES) and biolimus-eluting stents (BES) in all-comer patients.
  
  
  METHODS
  The EVERBIO II (Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents II) trial was a single-center, assessor-blinded study of 240 patients randomly assigned in a 1:1:1 ratio to EES, BES, or BVS. The only exclusion criterion was a reference vessel diameter >4.0 mm, which precluded treatment with BVS. The primary endpoint was angiographic late lumen loss (LLL) at 9 months. Secondary endpoints included patient-oriented major acute coronary events (MACE) (death, myocardial infarction [MI], and any revascularization), device-oriented MACE (cardiac death, MI, and target lesion revascularization), and stent thrombosis at the 9-month clinical follow-up.
  
  
  RESULTS
  Follow-up angiography was performed in 216 patients (90.7%) at 9 months. In-stent LLL was similar between patients treated with BVS (0.28 ± 0.39 mm) and those treated with EES/BES (0.25 ± 0.36 mm; p = 0.30). Clinical outcomes were similar at 9 months: the patient-oriented MACE rate was 27% in BVS and 26% in the EES/BES group (p = 0.83) and the device-oriented MACE rate was 12% in BVS and 9% in the EES/BES group (p = 0.6).
  
  
  CONCLUSIONS
  New-generation metallic DES (EES/BES) were not superior to BVS in terms of angiographic LLL and clinical outcomes. (Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents [EVERBIO II]; NCT01711931).
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Serban
authors.initials: S
authors.lastname: Puricel
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Diego
authors.initials: D
authors.lastname: Arroyo
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Noé
authors.initials: N
authors.lastname: Corpataux
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Gérard
authors.initials: G
authors.lastname: Baeriswyl
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Sonja
authors.initials: S
authors.lastname: Lehmann
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Zacharenia
authors.initials: Z
authors.lastname: Kallinikou
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Olivier
authors.initials: O
authors.lastname: Muller
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Ludovic
authors.initials: L
authors.lastname: Allard
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Stauffer
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Mario
authors.initials: M
authors.lastname: Togni
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland.
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Goy
authors.affiliation: Department of Cardiology, Fribourg University and Hospital, Fribourg, Switzerland. Electronic address: stephane.cook@unifr.ch.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Cook
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000601:surgery*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008422:Materials Testing / Q000379:methods; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; C518022:umirolimus; D020123:Sirolimus
keywords: coronary artery disease; drug-eluting stent(s); late lumen loss; myocardial infarction; percutaneous coronary intervention